Thyrocare Technologies Ltd.Q2 revenue +25%, PAT +26%, NHL sale ₹141 Cr, pregnancy kit

Thyrocare Technologies' Q2 FY27 call, held on 29 October 2026, reported consolidated revenue of ₹271 crore, up 25%, with pathology up 27% on 27% higher test volume, a gross margin of 74.2%, an EBITDA margin of 33% and profit after tax before exceptions of ₹60 crore, up 26%.

The franchise base reached a record 12,911 after about 1,180 additions, the most in three years. The company is selling its radiology unit, Nueclear Healthcare, to Trovera for ₹141 crore, and took a non-cash impairment of ₹45 crore in the consolidated books while shareholder approval is pending. It launched a ₹60 pregnancy test kit with a half-price lab confirmation, which management says will not add to earnings for at least three quarters, and is building specialty diagnostics, now about 4% of pathology revenue.

Net cash was ₹211 crore with no debt. Management raised its yearly revenue growth estimate to the early 20s, anchors the EBITDA margin at about 31% to 31.5%, and said there is no plan for a merger with API Group until the group is profitable without Thyrocare.